Home›Stocks›ACRV

ACRV — structural market context

Acrivon Therapeutics, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 21. Each line shows the earlier value, the later value and their dates.

Price

Close $1.82 (Oct 21) vs $1.79 (Oct 20): +1.67%.

Volume

0.64× its 20-session average (249K) on Oct 21.

Includes pre- and post-market trading.

Short interest

Short interest 1.6M shares (settlement Sep 30) vs 1.2M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 213 shares on Sep 29.

Previous file (settlements Sep 1–Sep 14, published Sep 30): no fails listed.

No new publication in this window.

Insider filings (Form 4)

None recorded in this window.

ACRV short interest & days to cover

SHARES SHORT
1.6M
% OF FLOAT
6.3%
DAYS TO COVER
4.4
CHANGE VS PRIOR
+34.4%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (22d ago)

ACRV fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-29 · 23d213$2.06
2026-08-14 · 69d3K$1.85
2026-08-03 · 80d1$1.5

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

ACRV insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 8 sales

InsiderTypeSharesValueFiled
Miller Mary · officer: Chief Legal OfficerSale (S)294$5852026-10-07
Blume-Jensen Peter · director, officer: President and CEOSale (S)14K$31K2026-08-27
Gamelin Erick · officer: Chief Development OfficerSale (S)400$8042026-08-20
Blume-Jensen Peter · director, officer: President and CEOSale (S)1K$2K2026-08-20
Peterson Katharine · officer: Chief Accounting OfficerSale (S)101$2032026-08-20

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Frequently asked questions

What is ACRV's short interest?
As of the FINRA settlement date 2026-09-30, ACRV had 1.6M shares sold short — 6.3% of its float, with 4.4 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying ACRV?
In the last 12 months of SEC Form 4 filings, ACRV recorded 0 insider purchases and 8 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell ACRV?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with A

AA · Alcoa CorporationAADX · Applied Aerospace & Defense, IAAPG · Ascentage Pharma Group InternaAAPL · Apple Inc.AAUC · Allied Gold CorporationAAVMY · ABN AMRO BK N V AMSTERDAM BRHAll A →

ACRV: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.